Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：1

作者：

Moehler, M. ^{[1
]}

Wyrwicz, L. ^{[2
]}

Chen, C. ^{[3
]}

Davenport, E. ^{[4
]}

Wang, J. ^{[4
]}

Nathani, R. ^{[3
]}

Kondo, K. ^{[3
]}

Elimova, E. ^{[5
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Mainz, Germany

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] RTI Int, Res Triangle Pk, NC USA

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-10

引用

页码：S185 / S185

页数：1

共 50 条

[31] Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
CANCER RESEARCH, 2023, 83 (08)
[32] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
Cruz-Correa, Marcia
Xu, Rui-Hua
Moehler, Markus H.
Oh, Do-Youn
Kato, Ken
Spigel, David R.
Arkenau, Hendrik-Tobias
Tabernero, Josep
Zimina, Anastasia V.
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Hirano, Hidekazu
Wyrwicz, Lucjan S.
Pazo Cid, Roberto
Xu, Hui
Sheng, Tao
Barnes, Gisoo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
[33] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
Lin, D.
Quan, W.
Garretson, M.
Chirikov, V. V.
Chen, C.
Singh, P.
Davis, C.
Sugarman, R.
ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
[34] Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
Lin, Daniel
Quan, Wenying
Garretson, Marne
Chirikov, Viktor
Chen, Clara
Singh, Prianka
Davis, Catherine
Sugarman, Ryan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Janjigian, Yelena Y.
Ajani, Jaffer A.
Moehler, Markus
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Karamouzis, Michalis
Bruges, Ricardo
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshi
Tehfe, Mustapha
Zander, Thomas
Kowalyszyn, Ruben
Pazo-Cid, Roberto
Schenker, Michael
Feeny, Kynan
Wang, Rui
Lei, Ming
Chen, Clara
Nathani, Raheel
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
[36] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
Cao, Xueqiong
Zhang, Mingming
Li, Na
Zheng, Bin
Liu, Maobai
Song, Xiaobing
Cai, Hongfu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[37] Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).
Van Cutsem, Eric
Singh, Prianka
Cleary, James M.
Kelly, Ronan Joseph
Moehler, Markus H.
Kuzdzal, Jaroslaw
Mendez, Guillermo
Motoyama, Satoru
Elimova, Elena
Grootscholten, Cecile
Sun Xiaowu
Taylor, Fiona
Lawrance, Rachael
Padilla, Brad
Moreno-Koehler, Alejandro
Zhang, Jenny
Blum, Steven, I
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[38] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Daniel Lin
Hiep Nguyen
Ruchit Shah
Yao Qiao
John Hartman
Ryan Sugarman
Gastric Cancer, 2023, 26 : 415 - 424
[39] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Lin, Daniel
Nguyen, Hiep
Shah, Ruchit
Qiao, Yao
Hartman, John
Sugarman, Ryan
GASTRIC CANCER, 2023, 26 (03) : 415 - 424
[40] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
Felip, E.
Wang, C.
Ciuleanu, T-E.
Saylors, G.
Tanaka, F.
Chen, K-N.
Ito, H.
Girard, N.
Lu, S.
Provencio Pulla, M.
Mitsudomi, T.
Awad, M.
Forde, P. M.
Lawrance, R.
Taylor, F.
Worthy, G.
Blum, S. I.
Vo, L.
Cai, J. L.
Spicer, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S973 - S974

← 1 2 3 4 5 →